Overview 
Prime Therapeutics (Prime) is excited to announce new, cost-effective Humira® biosimilar solutions, offering clients continued flexibility and choice. Beginning in 2025, Prime will offer four biosimilar manufacturer partners, including Organon (Hadlima®), Teva (Simlandi®), Sandoz (adalimumab-adaz), and Celltrion (adalimumab-aaty). Prime will retain Humira in a parity position to the four covered biosimilars.

Value to our biosimilar solutions 
Prime’s new biosimilar solution reflects our distinctive conflict-free approach to the prescription drug supply chain model by offering clients access to biosimilar therapies through a broad network of quality specialty pharmacies. 

We believe adding these solutions will deliver options to the market that offer providers, pharmacies and members more choice. Additionally, Prime’s strategy has strong biosimilar pipelines, ensuring long-term market success and stable access to therapies. Prime also supports efforts of biosimilar manufacturers to provide member support to keep out-of-pocket costs affordable.